IPF Clinical Course, Patient Outcomes, and Healthcare Resource Utilization


Science & Innovation Theater Webinar 

Recorded on August 31, 2016 

Sponsored by Boehringer Ingelheim 

 Click here to download PDF of presentation 


In this presentation, a distinguished speaker reviews 2 studies recently published in BMC Pulmonary Medicine and Respiratory Medicine examining the effects of forced vital capacity (FVC) decline and suspected early acute idiopathic pulmonary fibrosis (IPF) exacerbations on clinical outcomes and healthcare resource utilization (HRU). The studies are based on retrospective chart reviews conducted by a group of pulmonologists from around the United States.

The studies conclude that:

  • Greater FVC decline is associated with worse clinical outcomes and increased IPF-related HRU (BMC Pulmonary Medicine)
  • There is a substantial burden associated with early suspected acute IPF exacerbations on patients and the healthcare system (Respiratory Medicine)
  • Management options that address FVC decline and acute IPF exacerbations may help to improve health outcomes in patients with IPF


Steven D. Nathan, MD, FCCP
Inova Fairfax Hospital
Medical Director, Lung Transplant Program
Director, Advanced Lung Disease Program
Co-director, Pulmonary Hypertension Program

This webinar is sponsored, developed and presented by the sponsor.  The content of the Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of the Academy of Managed Care Pharmacy. 

Sponsored by:  

  Boehringer Ingelheim Webinar Logo